Podcasts about Obesity

80% of Americans are metabolically unhealthy, which means the obesity conversation isn't about weight for a lot of people... It's about internal health markers that indicate a declining state of metabolic function regardless of what someone weighs. Inside today's episode, I get into the harder version of the obesity conversation including whether it should be classified as a chronic medical condition, what happens when we label people as broken and then sell them the solution to their "brokenness", and where the personal responsibility conversation sits in a landscape flooded with GLP-1 medications and food environments engineered to defeat every mechanism the body has for satiety.Topics discussed: - The 80% Metabolically Unhealthy Statistic- Obesity as a Chronic Medical Condition- The Broken Mindset Trap- Personal Responsibility and Empowerment- Cardiovascular Risk, Longevity, and Children- Practices, Perceptions, and Physiology- Generational Parenting and Food Culture- The Chronic Dieting Flip Side---------- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠My Live Program for Coaches: The Functional Nutrition and Metabolism Specialization ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.metabolismschool.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- [Free] Metabolism School 101: The Video Series⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.metabolismschool.com/metabolism-101⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------Subscribe to My Youtube Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@sammillerscience?si=s1jcR6Im4GDHbw_1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grab a Copy of My New Book - Metabolism Made Simple⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- Stay Connected: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube: SamMillerScience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: The Nutrition Coaching Collaborative Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------“This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast and the show notes or the reliance on the information provided is to be done at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for educational purposes only. Always consult your physician before beginning any exercise program and users should not disregard, or delay in obtaining, medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. By accessing this Podcast, the listener acknowledges that the entire contents and design of this Podcast, are the property of Oracle Athletic Science LLC, or used by Oracle Athletic Science LLC with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this Podcast may save and use information contained in the Podcast only for personal or other non-commercial, educational purposes. No other use, including, without limitation, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of Oracle Athletic Science LLC, which may be requested by contacting the Oracle Athletic Science LLC by email at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠operations⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@sammillerscience.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. By accessing this Podcast, the listener acknowledges that Oracle Athletic Science LLC makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast."

Novo Nordisk Group General Counsel & Senior Vice President John Kuckelman speaks with Bloomberg's Dani Burger and Isabelle Lee after the company on Tuesday accused rival Eli Lilly of misleading advertising. Novo says that Lilly’s advertising campaigns rely on outdated weight-loss comparisons with lower doses of Novo’s own obesity shot Wegovy than what’s currently available, according to the complaint.See omnystudio.com/listener for privacy information.

Send us Fan MailAaron and Peaches sit down to talk Blue Angels flyovers, testosterone testing, military medicine, height-to-waist standards, and why the military has to get serious about health before people break.The episode starts with the Blue Angels beach flyover debate and whether something can be technically questionable while still being completely awesome. Then the guys get into the bigger conversation around the Department of War pushing testosterone checks for men over 30, why the military medical system has resisted basic hormone testing for years, and how operator syndrome, traumatic brain injuries, cortisol dysfunction, vitamin D deficiency, and low free testosterone can wreck performance and mental health.Aaron talks through his own fight to get blood work done, what the military missed, and why private-sector care finally helped him understand the difference between total testosterone and free testosterone.The conversation also hits height-to-waist standards, fat bodies in uniform, why some people will get flagged unfairly, and why most people need to stop making excuses. The bottom line: fitness is not just about looking good in uniform. It affects mental health, cognitive performance, readiness, durability, and who you become after the military.Check out Tasty Gains:TastyGains.comRegister for Operator Training Summit:OperatorTrainingSummit.comChapters:00:00 - Intro, Tasty Gains, and Operator Training Summit03:02 - Blue Angels Flyover Controversy03:39 - Unsafe vs. Inappropriate05:00 - Why Professionals Change the Risk Equation06:59 - Was the Flyover Necessary?08:22 - Pensacola, Nellis, and Airshow Culture09:20 - Testosterone Testing in the Military10:37 - What the Headlines Are Missing11:14 - Operator Syndrome and Low Testosterone12:11 - Fighting the Military Medical System12:55 - Vitamin D Deficiency in the Military14:34 - The Problem With “Normal” Testosterone Ranges16:00 - Trying to Raise Testosterone Naturally17:14 - Total Testosterone vs. Free Testosterone18:08 - TBI, Free Test, and Feeling Broken18:57 - Whoop Blood Work and Better Data19:19 - Breaking Down Institutional Resistance20:12 - Why This Could Lead to Better Screening21:02 - How the Referral System Fails People22:08 - Why Baseline Testing Matters22:34 - Trauma Medicine vs. Clinical Medicine23:55 - Military Medicine, COVID, and Bad Advice26:35 - Readiness Pressure and Medical Liability27:30 - SSRIs, Mental Health, and Missed Questions29:26 - The Military Health System Problem30:33 - Women, Hormones, and HRT30:42 - What to Ask Before Accepting Medication31:29 - Akron Bar Fight Story34:46 - Air Force Height-to-Waist Ratio35:11 - Body Composition Standards Come Back Around36:52 - Old BMI Standards and Fat Boy Programs37:19 - Height and Weight Charts39:41 - Peaches Tests the Calculator41:16 - When the Standard Misses Body Type42:40 - Trent's Monster Habit43:29 - Strategic Energy Drinks43:56 - Ten-Year-Old Crushes the Army PT Test45:30 - Kids, Discipline, and Internet Boundaries47:34 - Coaching Kids Through Hard Things48:25 - Wrestling Coach Motivation50:38 - Height-to-Waist and Job Performance51:40 - Human Performance and Mental Health52:34 - Obesity, COVID, and Comorbidities53:54 - Water, Sunlight, Nutrition, and Fitness55:26 - What People Cut First When Life Gets Busy55:42 - Sleep as a Performance Enhancer56:43 - Why Fitness Improves Mental Health58:26 - Confidence, Attraction, and Looking Better59:45 - Extrinsic Motivation Still Counts01:01:12 - Final Thoughts and Members-Only PreviewSupport the showJoin this channel to get access to perks: HEREBuzzsprout Subscription page:  HERERegister for our Operator Training Summit:  OperatorTrainingSummit.comFind an Air Force Recruiter: AirForce.comCollabs:Ones Ready - OnesReady.com 18A Fitness - Promo Code:  ONESREADY ATACLete - Follow the URL (no promo code):  ATACLeteDanger Close Apparel - Promo Code:  ONESREADYDFND Apparel...

In this episode, Nole and Kevin kick things off with a recap of Kevin's family trip to see Forrest Frank in Los Angeles, navigating the strange contrast of driving past old shooting and stabbing calls while the kids listen to worship music, mixed with some unfiltered thoughts on the absolute commercialism of modern Christian concerts ($100 t-shirts, anyone?).Then, the guys revisit a literal "hand grenade" question from a few weeks back: Can you be a good leader if you're obese? They pull no punches as they dive back into the uncomfortable truth about physical fitness, discipline, and why being afraid to hurt a brother's feelings can ultimately lead to watching them careen off a cliff. From the biblical charge to treat the body as a temple to the grit of summer "work hardening" in the heat, this conversation breaks down what we owe to our crews, our families, and ourselves. Finally, they tackle the shifting culture of the firehouse kitchen table, exploring how to guard camaraderie and tradition when everyone is on a different diet.Big thank you to My Epic and Facedown Records for the use of their song "Hail" in our podcast!https://www.youtube.com/watch?v=Dz2RZThURTU&ab_channel=FacedownRecordsThe Fire You Carry on YouTube.Sign up for a class at The Fire Up Program!https://www.fireupprogram.com/programsThe Fire Up Progam video.https://www.youtube.com/watch?v=I__ErPW46Ec&t=12s&ab_channel=FireUpProgramThe Fire You Carry Instagram.https://www.instagram.com/thefireyoucarry/Donate to The Fire Up Program.https://www.fireupprogram.com/donateThe Fire Up Program Instagram.https://www.instagram.com/fireup_program/Kevin's Instagram.https://www.instagram.com/kevinpwelsh/?hl=en

"Doc, do I need to take this forever?" It's one of the most common questions I hear in my office, whether it's someone's very first visit or someone who's already lost 30, 40, even 80 pounds and is feeling great. In this episode, I break down why your body fights so hard to regain weight after you lose it, and why that's biology, not failure. I walk through the new ATTAIN Maintain trial, a study of 376 adults who had already lost significant weight on tirzepatide or semaglutide, testing whether switching to an easier once-daily oral GLP-1 could help them keep the weight off, instead of just asking whether stopping medication causes regain. Maintenance isn't about staying on one medication forever. It's about having an individualized, active plan, and the ATTAIN Maintain data gives us more options than ever to build one. Episode Highlights: Why your metabolism and hunger hormones fight to reverse weight loss Lessons from the SURMOUNT-4 trial on what happens when treatment stops completely Inside the ATTAIN Maintain trial design and who was studied The weight maintenance results: oral medication vs. placebo Why maintenance therapy doesn't have to look like the treatment that got you there What actually goes into a sustainable long-term plan beyond medication Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

I told myself not to do it. I did it. I looked at my phone, got sucked in by my own curiosity, and was quickly reminded the world is overrun by axxholes, morons, and living demons.Subscribe over here, too: https://www.youtube.com/@WisdomFitnessAZGo to my site:https://SemperFryLLC.comCode: paratus for 15% OFF Exp. 7.31.2026BB Twittz: https://x.com/KristosCastJoin the Patreon with this link:https://www.patreon.com/c/KristosCastNew Channel on YT:https://www.youtube.com/@WisdomFitnessAZJoin Dr. Glidden's Membership site here:https://leavebigpharmabehind.com/?via=pgndhealth⁠Use Code: baalbusters for 25% OFFMake Dr. Glidden Your DoctorUse Code BB5 here for your 90 Essential Nutrients:https://www.azurestandard.com/shop/brand/azurewell/2326The Azure Whole Food Essential Nutrients are 1. Whole Food Multivitamin, 2. Alaskan Cod Liver Oil, 3. Fulvic-Humic Energy Blend, 4. IP6 Supreme. I also recommend adding the Core Copper.Use code BB5 for your discount.Be a Producer:https://GivesendGo.com/BaalBustershttps://buymeacoffee.com/BaalBustershttps://paypal.me/BaalBustersPodcast: https://www.spreaker.com/podcast/ba-al-busters-broadcast--5100262Become a supporter of this podcast: https://www.spreaker.com/podcast/ba-al-busters-broadcast--5100262/support.

Do you have trouble sleeping? An occasional late night or early morning is probably not dangerous, but too many people get too little sleep on a regular basis. How does that affect their health? Even more importantly, what can they do to change the situation? You'll want to listen to find out if you need a sleep reset. At The People's Pharmacy, we strive to bring you up to date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, July 18, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on July 20, 2026. The podcast will be available on Monday (July 20, 2026) Do You Need a Sleep Reset? Why is sleep so important for good health? Our guest is a sleep medicine specialist who uses a metaphor of Disneyland. Crucial maintenance on the theme park happens at night, when there are no visitors. Streets are cleaned, flower beds are weeded, and rides are inspected and, if needed, repaired. None of that can happen while the park is open for business. Our bodies and brains also need time for maintenance and repair, and some of that happens while we are sleeping. When we don't get the rest we need, we may find ourselves at increased risk for diabetes, cardiovascular problems, cancer, cognitive challenges and even premature death. Unfortunately, anxiety about not sleeping can keep people awake all on its own. How can people break that cycle? We'll also discuss ways that people can get help avoiding screens at night. That is an important part of a sleep reset. Blue light from the screen signals the brain to be alert instead of relax. Scrolling social media can often be emotionally upsetting, which also makes it more difficult to fall asleep. Is Your Diet Keeping You Awake? Most of us recognize that a big midnight snack, á la Dagwood Bumstead of the Blondie comic, is probably not conducive to sleeping well. How does nighttime eating affect our circadian rhythm? Are there diets that we should avoid because of their impact on sleep? Dr. Seheult describes a study in which volunteers had their sleep stages monitored closely during the time they were consuming different diets (Obesity, July 2023). When they followed a high-fat, high-sugar diet, it disturbed the pattern of their brain waves during what should have been restorative sleep. How Do Sleep Problems Affect Eating Habits? A lot of us are aware that when we are sleep deprived, we are more inclined to become hangry and we may be less discerning about what we eat. A recent study shows that the sleep deprivation can have an effect even if it is fairly mild and short-term. Scientists recruited people who normally sleep seven to eight hours a night and asked them to stay up an extra hour and a half (Annals of Internal Medicine, July 7, 2026).  During the six weeks of that part of the experiment, people were less active during the day. They also ate more, so they gained about a pound, on average, during those six weeks. Presumably, disrupting sleep for a longer period of time would result in greater weight gain and metabolic disruption. Would a Ketogenic Diet Help with a Sleep Reset? A ketogenic diet, in which the body relies on ketones rather than glucose for energy production, may be helpful. In particular, fasting overnight for at least 14 hours helps the body do what it must during sleep time. To figure out when you should stop eating, identify when you usually start to feel sleepy. That should be your bedtime. Having your last meal of the day about three hours before that will generally offer enough time for digestion so that you don't experience reflux in the middle of the night. Morning Light and Afternoon Naps Your sleep reset may depend on getting your own circadian rhythm to synchronize with the rest of the world. That is where early exposure to morning light comes in. It's beginning to feel a bit like The People's Pharmacy is on repeat: get morning light exposure! It sets your system up for feeling awake and alert during the day and starting to feel sleepy as the light fades in the evening. Obviously, this is most helpful for people who work during daylight hours. Those working overnight shifts would have to organize their days differently. People who have trouble falling asleep may be tempted to take a nap in the afternoon to make up for the lost sleep. That could be a mistake, as it relieves the sleep pressure that helps people fall asleep without trying. Learning to Fall Asleep If you interact with parents of very young children, you may have heard of sleep training. People have strong feelings about this, both pro and con. Adults rarely need sleep training, though. What we are more likely to need is “not-sleeping un-training.” Too many people approach the bedroom as though it were a stage, and sleep is the performance. No wonder they may develop some performance anxiety about sleeping! Other individuals have learned to associate the bedroom with tossing, turning and watching the clock. Consequently, their bodies tense up instead of relaxing when they get between the sheets. There is no easy quick fix for this problem, but cognitive behavior therapy for insomnia has been proven effective for most people. How About PM Pain Relievers? Even though there isn't an easy fix for sleep troubles, many people want one. They reach for the PM pain reliever and hope it will offer them a good night's sleep without a prescription. The “PM” part of that pain reliever is an old-fashioned antihistamine called diphenhydramine. You might be more familiar with its brand name: Benadryl. You'll also find it in Tylenol PM, Advil PM and all the other PM meds because it tends to make people feel drowsy. What's wrong with that? To start with, it isn't clear that it remains effective after a week or two. In addition, people with restless leg syndrome often find that it makes their condition worse. Other folks report that diphenhydramine can result in an unpleasant “hangover” the next day, in which they feel drowsy though not asleep for a good part of their waking hours. What Wakes You Up at Night? If your sleep problem is waking in the wee hours and having trouble getting back to sleep, you should consider the possibility that you have sleep apnea. The REM sleep of those early morning hours is not as deep as some other sleep stages. Consequently, an alarm signal from your brain saying you haven't taken a breath for 20 or 30 seconds may be more likely to wake you. Sleep apnea may be treated by providing air so that the pressure props the collapsing airway open. We discuss this in greater detail along with a new alternative to a CPAP machine in the podcast for this week. This Week’s Guest Dr. Roger Seheult is an Associate Clinical Professor at the University of California, Riverside School of Medicine. He is also an Assistant Clinical Professor at the School of Medicine and Allied Health at Loma Linda University. He is quadruple board-certified in Internal Medicine, Pulmonary Diseases, Critical Care Medicine, and Sleep Medicine through the American Board of Internal Medicine. His current practice is in Beaumont, California. He is a critical care physician, pulmonologist, and sleep physician at Optum California. Dr. Seheult lectures routinely across the country at conferences and for medical, PA, and RT societies. He is the director of a sleep lab and the Medical Director for the Crafton Hills College Respiratory Care Program. He is co-founder and presenter for MedCram.com, a site that offers concise and easy-to-follow medical videos on a range of topics. Roger Seheult, MD, MedCram, Loma Linda, UC-Riverside Listen to the Podcast The podcast of this program will be available Monday, July 20, 2026, after broadcast on July 18. You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

A new report from the Health and Social Care Committee says customers are being pushed towards products high in fat, sugar and salt which are typically cheaper than more nutritious food and that the government's food policy needs overhauling. The chair of the committee, Liberal Democrat MP Layla Moran, talks to Nuala McGovern about their recommendations.New analysis in The Economist suggests after years of progress fewer women are reaching executive positions and there may be signs that younger women are becoming less interested in promotion. Nuala McGovern speaks to the author of that analysis and a woman who left an executive role to rebalance her life. We hear from Sarah Ruggins who recently broke the world record for cycling the length of Europe - a distance of over 6,000 kilometres – double the length of the Tour de France. She only started cycling three years ago having spent a decade recovering from a condition that saw her bedridden and immobile – Complex Regional Pain Syndrome, one of medicine's most painful conditions. Sarah now holds three ultra-cycling records.Known at one point as the Diana of the Middle East and the rose of the desert, Asma al-Assad, the wife of Syrian President Bashar al-Assad, quickly became a well-known face around the world. But just how much do we know about the London-born former First Lady and the role she played in her dictator husband's oppressive dictatorship where peaceful protests against his regime were violently repressed, eventually leading to 13 years of civil war that saw more than half a million people killed. Nuala speaks to investigative journalist Chloe Hadjimatheou about her new podcast, We Call Her Emma. Presenter: Nuala McGovern Producer: Kirsty Starkey

Send us Fan MailBlood-brain barrier as a dynamic interface allowing selective passage of nutrients, peptides, and gut hormones.TOPICS DISCUSSED:Blood-Brain Barrier Structure: Capillary endothelial cells with tight junctions, absent fenestrae, and minimal vesicles create a selective interface; supported by astrocytes and pericytes.Crossing Mechanisms: Lipid-soluble small molecules diffuse passively; glucose, amino acids, and regulatory peptides use saturable transporters whose rates vary by need.Peptide Transport: Many peptides cross via lipid solubility or specific transporters; rate, not all-or-none presence, determines biological relevance; efflux systems remove some (e.g. certain enkephalins).Dynamic Regulation: Transporters for leptin and insulin are modulated by epinephrine, triglycerides, and brain demand; changes occur in aging and Alzheimer's (reduced glucose uptake, impaired Aβ efflux).Circumventricular Organs: Leaky capillary regions allow rapid sampling of blood signals while tanycytes limit spread to surrounding brain tissue.Drug Delivery Challenges: Small lipid-soluble drugs, barrier disruption (e.g. focused ultrasound), and “Trojan-horse” strategies each have limitations; intranasal delivery shows rapid brain distribution.Peptides & Brain Effects: Gut peptides like GLP-1 analogs, insulin, and ghrelin influence cognition and memory; brain entry predicts central effects.GUEST: William Banks, MD is a physician-scientist and leading researcher on the blood-brain barrier. He has focused on humoral brain-body communication, peptide transport, and the barrier's role in health and disease.RELATED CONTENT:M&M 298 | GLP-1s & Novel Peptides in Obesity, Diabetes & Metabolic Health | Katrin SvenssonSupport the showSupport my work:Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.For all the ways you can support my efforts.

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Are secondary VA claims getting denied more often in 2026? Has the VA changed the rules on secondary service connection?In this episode, we break down the truth about secondary VA claims, why the VA is scrutinizing nexus opinions more closely, and what veterans need to understand about medical evidence moving forward.We discuss: What secondary service connection actually means  The difference between causation and aggravation  Why weak nexus letters are getting challenged  Obesity as an intermediate step  Why some secondary claims succeed while others fail  The growing importance of detailed medical rationale  Common misconceptions veterans hear online  How strong medical evidence can impact VA appeals This episode is designed to help veterans better understand the medical side of secondary claims and the importance of evidence-based opinions in today's VA disability environment.Topics Covered Secondary VA claims in 2026  VA disability claims  Nexus letters  Aggravation claims  Sleep apnea secondary claims  Orthopedic secondary conditions  Medical evidence for VA claims  Independent medical opinions  Veteran disability appeals  VA claim denials About the PodcastThe Veterans Disability Nexus Podcast discusses VA disability medical evidence, nexus letters, DBQs, and the intersection of medicine and veterans disability claims. Hosted by medical professionals experienced in reviewing complex VA disability cases and independent medical opinions.DisclaimerThis podcast is for educational and informational purposes only and does not constitute legal or medical advice. Listening to this episode does not create a provider-patient relationship. Veterans should consult accredited representatives or qualified professionals regarding their individual claims or appeals.

Additional Resources:  ADCES Legislative Action Center OCAN Website OCAN Patient Roadmap  OCAN Advocacy Efforts Centers for Medicare and Medicaid Services (CMS) Website CMS GLP-1 Bridge FAQ CMS Eligibility website ADCES 2024 State Policy Forum Listen to more episodes of Diabetes Care Conversations at https://www.adces.org/practice/the-huddle-podcastLearn more about ADCES and the many benefits of membership at adces.org/join.The Diabetes Care Conversations Podcast is edited by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guest: Dr. Andrew Hogan is a Professor and Principal Investigator of the Obesity Immunology Research Group at Maynooth University. He discusses how obesity drives chronic inflammation and immune dysfunction, increasing the risk of diseases such as diabetes and cancer, while highlighting the immune system’s role in disease progression. He also explains how GLP-1 therapies improve both metabolism and immune function, offering new insights into obesity treatment. Featured Products and Resources: Request your free EasySep sample and share your experience for a chance to win prizes worth up to $3,000! Win 350 US dollars or equivalent toward refreshments to fuel your journal club discussions. The Immunology Science Round Up Innate Immunity Predicts Symptoms – Stronger innate immune responses predisposed people to influenza symptoms while also promoting antiviral immune activation. Broad HIV Neutralization #1 – A novel HIV immunogen induced broadly neutralizing antibodies in macaques, providing a promising blueprint for HIV vaccine development. Broad HIV Neutralization #2 – A germline-targeting vaccine induced broadly neutralizing HIV antibodies in nonhuman primates. CAR-T Targets Glioblastoma – A dual-targeting CAR-T therapy achieved durable glioblastoma control in preclinical models. Image courtesy of Dr. Andrew Hogan Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Professor Donal O'Shea, HSE National Clinical Lead on Obesity

If you've seen headlines linking Ozempic and other GLP-1 medications to sudden eye strokes, I want to stop the panic right here.  In this episode, I break down what the research on NAION actually shows, who's really at risk, and why the scary relative-risk numbers you're seeing online don't tell the whole story. I walk you through what NAION is, why patients on semaglutide often already carry the underlying risk factors that get left out of the clickbait, and what the difference is between an observational study raising a signal and a randomized trial proving cause and effect. I also share the warning signs that mean you should go to the ER immediately, not wait for your next appointment. You'll walk away knowing exactly how to think about this headline, what questions to bring to your own doctor, and why staying on your medication is usually the right call. Episode Highlights: What NAION is and how it affects the optic nerve The risk factors patients on GLP-1s often already have What the 37-million-person study actually found — and didn't Why randomized trials tell a different story than observational data Absolute risk vs. relative risk, explained simply Warning signs that mean go to the ER now Why sleep apnea complicates the whole picture Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Jim Ryan, ABC News National Correspondent joins Megan Lynch to talk about the use of GLP-1's has reached a new high.

Send us Fan MailToday we're releasing a new episode from a brand new series called the Boundless Body Radio Heritage Series! I wanted to do something extra special to celebrate 1,000 podcast episodes recorded here at Boundless Body Radio, a milestone that we hit on June 24, 2026!These episodes are actually not new, although they might be new to you! When we first got started back in October, 2020, I was so fortunate that so many incredible people said "YES" to being hosted on the show, however, we didn't have very many listeners at the time!Today, we get thousands of downloads every single month, and are usually included in the top 150 Fitness and Nutrition Podcasts on the Apple Podcast charts!To honor our amazing guests, I will be selecting one of those original episodes and posting them here on for this special series!As I was going through these episodes again, I remembered how valuable these conversations actually were. it was really striking how much the information these experts have shared has born out to be even more accurate several years later.The audio quality of a show was not as good back then as it is now, but I still really hope you enjoy these episodes, and find them relevant and helpful to you today!Cheers, thanks as always for listening, and I really hope you enjoy this episode of the Boundless Body Radio Heritage Series!Ben Bikman, PhD, is a returning guest on our show! Be sure to check out his first appearance on Boundless Body Radio, way back on episode 30, which is the most popular episode we've ever recorded!His sensational book, Why We Get Sick: The Hidden Epidemic at the Root of Most Chronic Disease-and How to Fight It offers a thought provoking yet real solution to insulin resistance and suggests how readers can reverse pre-diabetes, improve brain function, shed fat, and prevent diabetes.Find Dr. Bikman at-IG- benbikmandphdInsulin IQFind Boundless Body at-myboundlessbody.comBook a session with us here! 

Some Americans are panicking at the recent so-called outbreak of "explosive diarrhea." The news is reporting hundreds of cases nationwide. But according to the AAFP, "acute diarrheal disease accounts for 179 million outpatient visits annually in the United States." So there is no sudden outbreak of disease, and the suppose culprit, the Cyclospora parasite, is only suspected but not proven to have caused the diarrhea. Strangely, a Meta data center recently dumped contaminated water into public sewers, spreading what they said was Cupriavidus gilardii, which can also cause diarrhea. Taco Bell, famous for its diarrhea aftereffects, has begun removing certain vegetables from their menu since produce is being blamed for the so-called outbreak. Whatever truth there may be to this should be overshadowed by the fact that produce is only contaminated because large scale in industrial farms often are polluted by animal agriculture, or animal feces is sprayed directly on the produce via collected water. Is it possible that this diarrhea is simply a byproduct of the poor American diet, severely deficient in fiber and burdened by excess protein. Both of these problems can separately cause diarrhea, but together are certainly essential cause. Other developed countries have a third the number of annual U.S. diarrhea cases. So what is happening?https://www.usatoday.com/story/graphics/2026/07/09/maps-explosive-diarrhea-outbreak-cyclosporiasis/90862952007/https://apnews.com/article/cyclospora-outbreak-michigan-31e5e0034d39e85c844065a2bd593ecbhttps://www.aafp.org/afp/2022/0700/acute-diarrheahttps://www.theguardian.com/us-news/2026/jul/08/meta-datacenter-ai-wyoming-waterhttps://nypost.com/2026/07/09/lifestyle/taco-bell-pulls-ingredients-off-menu-as-explosive-diarrhea-parasite-cases-surge/?sr_share=facebook&utm_source=facebook&utm_campaign=nypost&utm_medium=social&fbclid=IwY2xjawS9E9xleHRuA2FlbQIxMABicmlkETJuVDdFSUFWME1HWXF4U1dNc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHsE7Yg3iMVCLTmtIsf61LLM61x7QdmHwTLcDJjgZAG8eO4DkhF4mKH38-64b_aem_YV9NJe_qxxvUnK9FraFLbQ*The is the FREE archive, which includes advertisements. If you want an ad-free experience, subscribe below.

When you start looking into GLP-1s and weight loss drugs, the amount of information, both good and bad, can become quite confusing.National Clinical Lead for Obesity at the HSE, Donal O'Shea, joins Shane to cut through the noise and discuss what you should know.

In this episode of Girl Talk with Tay, I sit down with Bracha Banayan, family nurse practitioner, entrepreneur, and founder of IVDrips and Hello Dose, for one of our most fascinating conversations yet. We dive into the science behind GLP-1 medications, why they're about so much more than weight loss, and how they're changing the conversation around longevity, metabolic health, and healthy aging.Bracha explains how GLP-1s work in the body, why weight gain is often rooted in biology rather than willpower, and how factors like glucose, insulin, inflammation, and hormones all play a role in long-term health. We also discuss who may benefit from GLP-1 medications, including women navigating perimenopause and menopause, adults focused on cardiovascular health, and those looking to improve metabolic wellness.We also get into fertility, blood sugar, continuous glucose monitors, and the surprising ways GLP-1s may help reduce cravings by working on the brain's reward system. Beyond medications, Bracha shares the foundational habits she believes everyone should prioritize first from walking after meals and getting morning sunlight to improving sleep and building sustainable wellness routines.Whether you're curious about GLP-1s, trying to better understand metabolic health, or looking for practical ways to optimize your health for the long run, this episode is packed with insights and actionable takeaways.xo, Tay⸻Follow Bracha Banayan!

On this special episode of Inside Business recorded at EY's head office, host Ciarán Hancock is joined by Dr Harriet Treacy, founder and CEO of BeyondBMI, Ireland's first online medically led weight management and obesity clinic.She explains how frustration at the inefficiencies of healthcare systems was the catalyst in her decision to pivot from a medical doctor to an entrepreneur.Harriet is a finalist in the Emerging category for the 2026 EY Entrepreneur of the Year awards.Also on this episode, is Tommy Kearns, CEO and co-founder of customer engagement platform Xtremepush. The company helps legacy media transition to digital, and new companies that have emerged over the last decade or so. Tommy also outlines the pivotal role AI is playing in the company's present and future.Tommy is a finalist in the Established category for the 2026 EY Entrepreneur of the Year awards.Plus, we also hear from Roger Wallace, Head of Assurance & EY Entrepreneur of the Year Partner Lead at EY Ireland, on how AI is being implemented in the company's business – the level of investment needed and the impact on employee roles. Roger also highlights the value of our indigenous entrepreneurs against the backdrop of our economy being driven by overseas investment.Produced by John Casey. Hosted on Acast. See acast.com/privacy for more information.

Resources for the Community:___________________________________________________________________Linktree Our Favorite ThingsNeed help appealing your GLP-1 dials?www.FindHonestCare.com/KimFind Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________While Kim takes time away following the loss of her sister, we're revisiting some of our most impactful conversations from Season 1. Thank you for supporting The Plus SideZ Podcast and this community during this time.Why do GLP-1 medications work when years of dieting and exercise often don't?In this episode, obesity medicine physician Dr. Matea Rentea explains why obesity is more than willpower. Through expert insight and a powerful patient story, we explore the science behind obesity, metabolism, hormones, and why "eat less, move more" often isn't enough.In this episode:• Why diets fail for many people living with obesity• How hormones and metabolism affect weight loss• Why GLP-1 medications work differently• The role of exercise, mental health, and weight stigma• Real patient experiences alongside evidence-based medicineWhether you're new to GLP-1s or have been with us since Season 1, this conversation remains one of our most requested episodes.This episode was originally recorded in Season 1. Medical information reflects what was known at the time of recording. Always talk with your healthcare provider before making medical decisions. Follow Dr. Rentea https://www.renteaclinic.com/ ______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail!Use Honest Care to Appeal GLP-1 Denials. Go to HonestCare.com/Kim  Honest Care can Appeal GLP-1 Denials. Go to FindHonestCare.com/Kim Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Send us Fan MailCan We Prevent Muscle Loss While Taking GLP-1 Weight-Loss Drugs?GLP-1 medications like Zepbound have changed the way we treat obesity. But as more people lose significant amounts of weight, another question has emerged:What happens to your muscle?It's normal to lose some lean mass—including muscle—during weight loss. But researchers are now asking whether preserving more muscle could improve long-term health, particularly as we age.In this episode, Dr. Eeks speaks with Dr. Richard Pratley, lead author of a new randomized, double-blind, placebo-controlled clinical trial investigating whether an investigational antibody called apitegromab can help preserve lean mass in people taking tirzepatide (Zepbound).Together they discuss:• Why people lose lean mass during weight loss• What "lean mass" actually means—and why it matters• Why muscle preservation has become one of the biggest new questions in obesity medicine• How apitegromab works by blocking myostatin—a protein that acts like a brake on muscle growth• The results of the study and how much lean mass participants preserved• Why preserving lean mass doesn't automatically mean preserving strength• Whether concerns about muscle loss on GLP-1 medications have become exaggerated• The importance of resistance training and adequate protein during weight loss• Whether future obesity treatment will focus less on body weight and more on body composition• The bigger question: Are we entering an era where one medication leads to another—or is there a better path???This conversation explores one of the most interesting—and practical—questions in obesity research today: Can we lose fat without sacrificing too much muscle?Work with me? Perhaps we are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow on X. Or Facebook here.On Youtube.Or TikTok.SUBSCRIBE to her Newsletter here! (the bits not posted on socia media)Support the show

Have you ever looked in the mirror and wondered, "Why is it so much harder to lose weight than it used to be?" Maybe you've tried the diets... counted the calories... exercised faithfully... only to watch the scale refuse to budge. What if the problem isn't a lack of willpower? What if we've been asking the wrong question all along?Today on Call IT in With Dar, I'm joined by Dr. William Summers, a physician with more than 36 years of experience helping people understand the science behind obesity. As a board-certified OB/GYN and medical weight management specialist, Dr. Summers believes it's time we stop blaming ourselves and start recognizing obesity for what it truly is—a complex medical condition influenced by biology, hormones, metabolism, and our modern environment.  In this myth-busting conversation, we'll explore why obesity has become one of the greatest health challenges of our time, what new research is revealing, how medications like Ozempic and Mounjaro are changing the conversation, and most importantly, why compassion and understanding are far more powerful than guilt and shame.  Whether you're struggling with your own weight, supporting someone you love, or simply wanting to separate fact from fiction, this episode offers clarity, hope, and practical insight.  Let's come together for this important conversation about obesity! Call It in with Dar! Support the showFull Show Notes can be found at CallITInPodcast.comPhoto credit: Rebecca Lange Photography Music credit: Kevin MacLeod Incompetech.com (licensed under Creative Commons)  Production credit: Erin Schenke @ Emerald Support Services LLC.Grab Dar's Flight Deck Oracle Card DeckTake Dar's Archetype Quiz

Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage.  Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification.  Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients."  "I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment." "Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine." #FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy fractyl.com Download the transcript here

Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage.  Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification.  Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients."  "I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment." "Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine." #FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy fractyl.com Listen to the podcast here

Anthony Auriemma, MD, discusses socioeconomic factors and healthcare system stigma can impact patient access to obesity care.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

The Centers for Medicare & Medicaid Services is expanding access to GLP-1 medications through the new Medicare GLP-1 Bridge program. Eligible beneficiaries will be able to receive the medications for $50 a month, though not everyone enrolled in Medicare will qualify. Subscribe to our newsletter to stay informed with the latest news from a leading Black-owned & controlled media company: https://aurn.com/newsletter Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Master MASLD/MASH diagnosis and multidisciplinary care. Credit available for this activity expires: 07/07/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/diagnosing-and-managing-obesity-linked-liver-disease-2026a1000ki0?ecd=bdc_podcast_libsyn_mscpedu

Read the bloghttps://rawfoodmealplanner.com/how-to-naturally-boost-glp-1/Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Weniger als vier von 100. So wenige gingen ein Jahr später noch ins Fitnessstudio. Und das lag nicht daran, dass sie nicht wollten.Fitness-Gewohnheiten – ob gesundes Essen, Supplement-Einnahme oder regelmäßiges Training – spielen neurobiologisch in einer eigenen Liga. Am Anfang arbeitet Dein Gehirn gegen Dich. Am Ende dieser Folge weißt Du, warum, und mit welchen drei Strategien Du trotzdem dranbleibst.Du erfährst:Warum sich die ersten Wochen wie ein Kampf anfühlen, und wann sich das drehtWarum die „21-Tage-Regel“ nicht funktioniert – und wie lange Du wirklich brauchst3 simple Strategien, die in Studien zu >50% häufigerem Training führen.Los geht's. Und dann: dranbleiben.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.

Luis and Camille riff on GLP-1s. They are not a silver bullet, nor do they teach you how to relate to food, but they can be a great temporary auto regulator and bridge while a new food relationship is built. In an era of overfed and undernourished people, Luis and Camille talk about how to get nutritional needs met. Resmaa Menakem speaks about culture vs strategy. Diet culture is a strategy. Our six month Embodied Nutrition Slow group, starting July 7, slowly and sustainably shifts the culture of how you relate to your body and what you consume. https://www.holisticlifenavigation.com/slow-practice-nutrition-groupContact us at info@holisticlifenavigation.com if you have any questions about the Embodied Nutrition Slow Group. You can get instant access to all of the HLN webinars and video courses here: https://hln.thinkific.com/collections You can order the book here: https://www.holisticlifenavigation.com/the-book----You can learn more on the website: https://www.holisticlifenavigation.com/You can follow Luis on Instagram @holistic.life.navigationQuestions? You can email us at info@holisticlifenavigation.com

The Silent Epidemic: Why Fatty Liver Disease Deserves Your AttentionThis is an incredibly important public health initiative, and I commend Liver Specialists of Texas and Houston Research Institute-Medical Center for offering free FibroScan screenings. Let me break down why this matters so much.The Hidden Danger of Fatty Liver DiseaseFatty liver disease has become alarmingly common—affecting nearly 1 in 3 American adults—yet it remains woefully under-diagnosed and under-treated. Many people dismiss it as a benign condition or assume nothing can be done. This is dangerously wrong.The progression is real: Fatty liver can advance to inflammation (steatohepatitis), then to fibrosis (scarring), and ultimately to cirrhosis—irreversible, severe scarring that can lead to liver failure and liver cancer. In fact, fatty liver disease is now one of the leading causes of liver transplantation in the United States.Risk Factors: A Metabolic Perfect StormThe risk factors you mentioned form what we call the "metabolic syndrome cluster":Obesity (especially abdominal fat)Type 2 diabetes or pre-diabetesHypertensionElevated cholesterol/triglyceridesEven having just one or two of these conditions significantly increases your risk. The liver becomes a repository for excess fat when metabolism goes awry, triggering inflammation and progressive damage.Hope on the HorizonHere's the good news: Fatty liver can be treated, stabilized, and even reversed—especially when caught early. There are now:FDA-approved therapies specifically for fatty liver diseasePromising clinical trials offering cutting-edge treatmentsLifestyle interventions that can make a dramatic differenceWhy Free FibroScan Screening MattersA FibroScan is a quick, painless, non-invasive test that measures liver stiffness (fibrosis) and fat content. Early detection is everything. By the time symptoms appear, significant damage may have already occurred.This initiative addresses a critical gap: awareness and screening. Too many people don't know they're at risk until it's too late. A free FibroScan removes barriers and could literally save lives.Take Action TodayDon't wait for symptoms. If you have any of the risk factors mentioned, take advantage of this opportunity.

Are they getting SWOLE AF in Vietnam? Are deadlifts necessary or are there other good options out there, what to do for knee issues and some Balls Deep videos that are hilarious. ALL LINKS: https://swolenormous.com

Obesity treatment has changed dramatically over the past decade. While nutrition and lifestyle remain the foundation of long-term metabolic health, today's medical landscape also includes bariatric surgery and GLP-1 medications as potential tools for certain individuals. In this episode, I sit down with board-certified bariatric surgeon and obesity medicine specialist Dr. Betsy Dovec to discuss how obesity treatment has evolved, who may benefit from bariatric surgery, how today's procedures differ from common misconceptions, and where GLP-1 medications fit into the conversation. Whether you've considered surgery yourself, are curious about today's obesity treatments, or simply want to better understand the options available, this episode offers a thoughtful, balanced discussion focused on long-term health—not just weight loss. In This Episode We Discuss: How bariatric surgery has changed over the years Who may be an appropriate candidate for weight loss surgery Common myths and misconceptions about bariatric surgery The role of GLP-1 medications in modern obesity treatment Why preserving muscle mass is essential during weight loss What happens when GLP-1 medications are discontinued The importance of protein, resistance training, and medical follow-up Looking beyond the scale to prioritize metabolic health and longevity Learn More About Dr. Betsy Dovec Website: https://bodybybariatrics.com/ Resources Mentioned ⭐ Feel Great System https://shanahussinwellness.com/feel-great-system/ ⭐ 90-Day Metabolic Reset https://shanahussinwellness.com/90-day-reset/ Let's Connect! Website: https://shanahussinwellness.com/ Instagram: https://www.instagram.com/shana.hussin.rdn/ Facebook: https://www.facebook.com/FastToHealWithShanaHussin My Courses & Programs ✔ Low Insulin Academy https://shanahussinwellness.com/programs-courses/low-insulin-academy-on-demand/ ✔ Cortisol Calm https://shanahussinwellness.com/programs-courses/cortisol-calm-signature-course/ If you enjoyed today's conversation, please share this episode with a friend or family member and consider leaving a rating and review. Your support helps us continue bringing you evidence-based conversations that empower you to take control of your metabolic health.

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Send us Fan MailEndogenous peptide diversity, GLP-1 drugs, and methods for novel peptide discovery.TOPICS DISCUSSED:Peptide Structure & Production: Short amino acid chains (3-50 residues) cleaved from larger precursors by PCSK enzymes, stored in dense-core vesicles, and released upon stimuli rather than acting as folded enzymes like proteins.Tissue-Specific Processing: The same precursor yields different peptides by tissue; preproglucagon produces glucagon in pancreas but GLP-1 in gut L-cells due to distinct cleavage patterns.Signaling Timescales: Peptides act over minutes via GPCRs and can drive longer transcriptional changes such as FOS expression, yet are cleared rapidly by proteases and kidneys.Endogenous GLP-1: Meal-stimulated incretin from gut that boosts insulin secretion with a half-life of only minutes, limiting primary action to periphery rather than deep brain structures.GLP-1 Engineering for Brain Access: DPP4 site mutations plus lipid conjugation enable albumin binding, extend half-life, and raise brain exposure.Dose-Dependent Effects: Low GLP-1 doses mainly lower blood glucose via pancreas; higher doses engage hindbrain and hypothalamic neurons to suppress appetite and alter food preference.Novel Peptide Discovery: Computational scans across the genome flag hundreds of uncharacterized precursors, facilitating new peptide discovery.BRP Peptide: This newly discovered brain-derived peptide suppresses feeding in GLP-1 receptor knockout mice, activates non-overlapping neurons, and does not slow gastric emptying.ABOUT THE GUEST: Katrin Svensson, PhD, is a biochemist and physiologist who leads a laboratory at Stanford University focused on peptide hormone physiology and the regulation of energy balance.PRACTICAL TAKEAWAYS:GLP-1 drugs require higher doses to engage brain satiety circuits for meaningful weight loss; lower doses primarily improve glucose control with little effect on appetite.Response varies widely across individuals, with some losing over 25% body weight while others see minimal change.Emerging peptides under study may suppress appetite via brain pathways that avoid the gastric slowing responsible for common GI side effects of current GLP-1 drugs.Research peptides purchased online frequently show variable purity below pharmaceutical standards and may contain unsafe formulation components or aggregates.Support the showSupport my work:Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.For all the ways you can support my efforts.

Most patients with metabolic dysfunction–associated steatotic liver disease (MASLD) go undiagnosed until significant liver damage has already occurred, despite the availability of simple, guideline-supported screening tools that remain notoriously underused in both primary care and weight management settings. That's according to a conversation between Naim Alkhouri, MD, chief medical officer at Summit Clinical Research and director of the Steatotic Liver Disease Program at the Clinical Research Institute of Ohio, and Chika Anekwe, MD, obesity medicine clinical director at the Massachusetts General Hospital Weight Center and an instructor in medicine at Harvard Medical School. In this episode of Beyond the Silo: Integrated Care Across the CRM Continuum, the third installment in a series examining the cardio-renal-metabolic continuum, Alkhouri and Anekwe discuss why MASLD and its more aggressive form, metabolic dysfunction–associated steatohepatitis (MASH), belong alongside the heart and kidney in conversations about cardiometabolic risk. The pair walk through how Fibrosis-4 Index for Liver Fibrosis calculations can identify high-risk patients before liver damage becomes irreversible, why ownership of screening often falls through the cracks between primary care, obesity medicine, and specialty clinics, and how the recent FDA approvals of resmetirom and semaglutide for MASH have raised the urgency of early detection. The conversation also covers strategies for closing equity gaps in liver disease screening, including the role of telehealth and artificial intelligence in extending care to underserved and rural communities.

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)What If Your Weight Struggle Was Never About Willpower?What if the reason some people struggle with their weight their entire lives has nothing to do with what they're eating or how hard they're trying — and everything to do with their DNA? It's a question that doesn't get asked nearly enough, and today, we're finally diving into it.For so many people living with severe obesity, the missing piece of the puzzle isn't a better diet plan or more motivation. It might be written right into their genetic code — and that changes everything about how it should be understood and treated.Today's guest is Dr. Jesse Richards — board-certified in internal medicine and obesity medicine, Director of Obesity Medicine at the University of Oklahoma School of Community Medicine, and the person his colleagues call when they have questions about the genetics of obesity. His research covers genetic obesity, GLP-1s, and novel treatments for obesity and substance use disorders. Safe to say, he knows this space better than almost anyone.In This Episode, We Cover:What Sparked Dr. Jesse's Interest in Genetic ObesityWhy Some People Are Born With a Stronger Genetic Drive Toward ObesityThe Genetic Syndromes Behind Severe Obesity That Most People Have Never Heard OfIt's Not in Your Head — But It Is in Your BiologyWhy Genetic Test Results Are Only Part of the StoryThis is just the surface — give the full episode a listen to get into everything we covered and more.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We break down Medicare's brand-new GLP-1 Bridge Program and explain why headlines are both true and incomplete. We lay out the real eligibility rules, the $50 copay promise, and the smarter questions to ask so you and your clinician can find the right coverage pathway. • why Medicare historically excludes weight loss medications and what changed with modern obesity medicine • what the GLP-1 Bridge Program is designed to do and why it is not universal coverage • the $50 copay detail and why office visits labs and deductibles can still affect total cost • who does not qualify because another Medicare Part D pathway may already apply • the three eligibility “doors” based on BMI and specific risk conditions • which GLP-1 medications are included at the time of recording and the planned program timeline • how to prepare for an appointment and the exact phrasing that helps your clinician pick the right route • why checking CMS and staying current matters as rules evolve You can send us an email, you can find us on Threads, follow us on Instagram, or leave us some fan mail.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

I hear this from so many of my patients: "Dr. Shelly, I haven't changed anything—not my diet, not my exercise—but I'm gaining weight and my body just doesn't respond the way it used to." If you're a woman in your 40s or 50s, you're probably nodding right now. In this episode, I'm walking you through exactly why menopause causes weight gain, why it has nothing to do with willpower, and what breakthrough new research reveals about Foundayo—an oral GLP-1 medication—and how it helps restore the biological signals that become harder to access during this life stage.  I'm sharing real data from the 2026 American Diabetes Association Scientific Conference, including results from the ATTAIN 1 and ATTAIN 2 clinical trials that show meaningful weight loss across all menopausal stages.  But here's what matters most: the goal during menopause isn't just weight loss—it's aging healthy. You'll learn exactly what that looks like and what you need to focus on right now. Episode Highlights: What menopause actually is ( How estrogen decline drives abdominal fat storage and insulin resistance Why muscle loss and poor sleep compound weight gain How GLP-1 medications work—and what they don't do The ATTAIN trials: weight loss results before, during, and after menopause Strength training, protein intake, and the non-negotiables for sustainable results REFERENCES: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2. Presented at the 86th Scientific Sessions of the American Diabetes Association, June 2026.   Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes. Lancet. 2026.   ClinicalTrials.gov. ATTAIN-2 Trial (NCT05872620).   The Menopause Society. Menopause practice recommendations and patient resources on metabolic changes during menopause. Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Today we cover injuries, overtraining, proper form, obesity, and much much more!All Links: https://swolenormous.com

Gluttony, stress, exhaustion, and unhealthy habits are often treated as merely physical problems. In this episode, Costi Hinn explains why these issues have spiritual implications and how believers can pursue a healthier, more faithful life.

I am delighted to have Dr. Ken Berry returning to the podcast for his fourth appearance today. He is a physician, bestselling author, and passionate advocate for health, known for his no-nonsense approach to wellness. Dr. Berry has practiced at the Berry Clinic since 2003 and is an active community member. He has a YouTube channel with more than 2 million subscribers- one of my favorite go-to resources for patients.  In our discussion today, we explore a recent Time news article and the growing concerns around the declining trustworthiness of media sources. We dive into the limitations of observational research, the problem with celebrity endorsements of ultra-processed foods, rising obesity rates in children and teens, and whether genetic factors are actually behind obesity, as highlighted recently in a 60 Minutes segment. We also discuss the impact of sugar, grains, and seed oils, as well as the significance of visceral fat. You will not want to miss this invaluable discussion with Dr. Ken Berry. IN THIS EPISODE YOU WILL LEARN: Dr. Berry breaks down some deeper issues surrounding the recent Time article, where a lone registered dietitian claimed that ultra-processed foods are acceptable. How media sources are losing their credibility The vital part social media plays in changing the narrative and holding media sources accountable Why consumers must stay informed and be proactive in their health choices  The health implications of eating ultra-processed foods Dr. Berry shares his concerns about the American Academy of Pediatrics recommending drugs like Ozempic for children.  The benefits of eating whole foods  Dr. Berry shares his three rules for a healthy diet. Why we need to avoid sugar and seed oils How following a low-carb diet can help reduce visceral fat. Dr. Berry introduces the American Diabetes Society and explains its mission. Bio:  Dr. Ken D. Berry, MD, is a licensed family physician, best-selling author, and leading advocate for the Proper Human Diet (PHD). With over two decades of clinical experience, Dr. Berry specializes in helping patients improve their health through low-carbohydrate, nutrient-dense eating. His best-selling book, "Lies My Doctor Told Me: Medical Myths That Can Harm Your Health," and his popular YouTube channel, which has over 3 million subscribers, provide accessible, evidence-based guidance on nutrition and wellness. Dr. Berry's mission is to empower individuals to reclaim their health by debunking common medical myths and promoting sustainable dietary and lifestyle changes. He is also a member of the Diet Doctor low-carb expert panel and an active participant in the keto and low-carb communities. Dr. Berry lives with his wife Neisha and their children on a farm in Holladay, Tennessee. Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Dr. Ken Berry On his ⁠website⁠ ⁠YouTube⁠ Dr. Berry's Books ⁠The American Diabetes Society ⁠

You're not over-fat. You're under-muscled. That single reframe changes how you think about your weight, your energy, and how well you'll age. Dr. Gabrielle Lyon, a fellowship-trained geriatrician and the founder of muscle-centric medicine, has spent her career arguing that we've fixated on the wrong organ. Obesity, insulin resistance, even cognitive decline don't start where you think. They start in your muscle. She breaks down why muscle is your metabolic currency, your body armor, and the closest thing we have to a longevity drug. And why the protein advice most people follow was set during wartime rationing, not built for the life you're trying to live. The hard part isn't the science. It's that the changes stay subtle until one day they're not. This conversation will make you rethink every plate of food and every workout you skip. Forever Strong: A New, Science-Based Strategy for Aging Well Amazon Ebook Audiobook Dr. Lyon on Instagram Dr. Lyon on YouTube DrGabrielleLyon.com In this episode you will: Discover why your muscle, not your body fat, is the real driver of metabolic health and survival Learn the leucine meal threshold and the protein number to hit at your first meal Understand anabolic resistance and why you need more protein, not less, as you age Uncover where the 0.8g/kg protein guideline actually came from and why it falls short Rethink cardio versus resistance training and build a plan that protects muscle for life For more information go to https://lewishowes.com/1940 For more Greatness text PODCAST to +1 (614) 350-3960 Follow The Daily Motivation for essential highlights from The School of Greatness More SOG episodes we think you'll love: Dr. Mark Hyman Dr. William Li Glucose Goddess TOPICS muscle-centric medicine, skeletal muscle, protein and longevity, leucine threshold, anabolic resistance, sarcopenia, insulin resistance, healthy aging, Dr. Gabrielle Lyon Get More From Lewis! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.